Abstracts tagged "Disease Activity"

Abstract Number: 699 • 2017 ACR/ARHP Annual Meeting
Impact of Anti-RBP Antibodies on Disease Activity and Quality-of-Life in Immunosuppressant Naive Systemic Lupus Erythematosus
Rene Bermea¹, Tammy Utset² and Kichul Ko³, ¹Medicine, University of Chicago, Chicago, IL, ²Medicine, Section of Rheumatology, University of Chicago, Chicago, IL, ³Medicine, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL
Background/Purpose: There is a lack of phenotypic data on SLE patients who have never been on immunosuppressive therapy. Anti-RNA binding protein (anti-RBP) antibodies (anti-Smith, anti-RNP,…
Abstract Number: 1241 • 2017 ACR/ARHP Annual Meeting
Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains
Gabriela L. Maica¹, Michelle Frits², Christine Iannaccone³, Taysir G. Mahmoud⁴, Clifton O. Bingham III⁵, Vivian P. Bykerk⁶, Michael Weinblatt⁷ and Nancy A. Shadick⁸, ¹Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Flare is an important, distinct feature of RA, often rendering patients immobile and contributing to a poor quality of life. Recently, there has been…
Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…
Abstract Number: 1848 • 2017 ACR/ARHP Annual Meeting
NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis (TA) and Relationship with Disease Activity
Ramnath Misra¹, Avinash Jain², Dinesh Kumar³, Durga Prasanna Misra⁴, Anupam Guleria⁵, Sandeep Kumar⁴, Atul Rawat³, Smriti Chaurasia⁴, Umesh Kumar⁶, Abhishek Zanwar⁴, Durgesh Dubey⁷, Ruchika Goel⁸, Debashish Danda⁹ and Paul Bacon¹⁰, ¹Clinical Immunology, Sanjay Gandhi Postgraduate of Medical Sciences, Lucknow, India, ²Clinical Immunology, Senior Resident, Lucknow, India, ³Centre for Biomedical Research, Lucknow, India, ⁴Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁵Centre for Biomedical Research, DST-INSPIRE Faculty, Lucknow, India, ⁶Centre for Biomedical Research, Research Scholar, Lucknow, India, ⁷Centre for Biomedical Research, PhD Student, Lucknow, India, ⁸Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ⁹Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹⁰Rheumatology, Emeritus Professor, Birmingham, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis of unknown pathogenesis. The current serological and radiological parameters used to assess disease activity are not…
Abstract Number: 2353 • 2017 ACR/ARHP Annual Meeting
The Relationship between Disease Activity, VEGF and E-Selectin Levels with Arterial Stiffness in Rheumatic Patients Treated with Biological Agents
Taskin Senturk¹, Huseyin Baygin¹, Gokhan Sargin¹, Hakan Akdam² and Mustafa Yilmaz³, ¹Rheumatology, Adnan Menderes University, Aydin, Turkey, ²Nephrology, Adnan Menderes University, Aydin, Turkey, ³Biochemistry, Adnan Menderes University, Aydin, Turkey
Background/Purpose: Rheumatic diseases are chronic-inflammatory disease associated with endothelial damage, changes in vascular permeability and plaque formation. VEGF and E-selectin play an important role in…
Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Seong-Min Kweon¹, Seung-Geun Lee², Ji-Heh Park², Eun-Kyoung Park³, Yun-Kyung Kim⁴, Geun-Tae Kim⁵ and Dong Hyun Sohn⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ²Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁴Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁵Kosin University College of Medicine, Busan, Korea, Republic of (South), ⁶Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South)
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…
Abstract Number: 2958 • 2017 ACR/ARHP Annual Meeting
Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus
Hermine I. Brunner¹, Michael J. Holland², Michael W. Beresford³, Nicolino Ruperto⁴, Stacy P. Ardoin⁵, Simone Appenzeller⁶, Clovis A Silva⁷, Glaucia V. Novak⁷, Daniela M. Lourenço⁸, Francisco Flores⁹, Beatrice Goilav¹⁰, Scott E. Wenderfer¹¹, Deborah M. Levy¹², Angelo Ravelli¹³, Raju Khubchandani¹⁴, Tadej Avcin¹⁵, Marisa S. Klein-Gitelman¹⁶, Brian M. Feldman¹⁷ and Jun Ying¹⁸, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁷Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁹Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ¹²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹³University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, ¹⁵Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ¹⁶Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ¹⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is characterized by changing disease activity: episodes of improvement are often followed by episodes of worsening, i.e. flares. Considering…
Abstract Number: 241 • 2017 ACR/ARHP Annual Meeting
Histological and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained By Ultrasound Guided Biopsy in Phase 1 of the Accelerating Medicines Partnership RA Network
Andrew Filer¹, Arthur M. Mandelin II², Edward F. DiCarlo³, Brendan Boyce⁴, Darren Tabechian⁵, Ralf G. Thiele⁶, Stephan Kelly⁷, Ellen M. Gravallese⁸, Diane Horowitz⁹, Kevin Wei¹⁰, Deepak Rao¹¹, Vivian P. Bykerk¹² and Jennifer H. Anolik¹³, ¹Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, Northwestern University, Chicago, IL, ³Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Queen Mary University of London, London, United Kingdom, ⁸Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA, ⁹Division of Rheumatology, North Shore - Long Island Jewish Health System, Woodbury, NY, ¹⁰Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Spring, IN, ¹²2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹³Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The AMP-RA network applies cutting edge technologies to the study of tissue obtained by ultrasound guided synovial biopsy from patients with rheumatoid arthritis (RA).…
Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
Abstract Number: 1251 • 2017 ACR/ARHP Annual Meeting
Chinese Patient Reported Index with Rheumatoid Arthritis (CPRI-RA): Reliability, Validity and Agreement with DAS28 and HAQ
Man Han¹, Xun Gong¹, Xiao-po Tang¹, Hong-xiao Liu², Jian Liu³, Xin-chang Wang⁴, Jun-li Zhang⁵, Shi Chen⁶, Qing-chun Huang⁷, Yong-fei Fang⁸, Qing-jun Wu⁹, Dong-yi He¹⁰, Zhen-bin Li¹¹, Yue Wang¹², Hong Jiang¹³, Ming-li Gao¹⁴, Wei Liu¹⁵, Ying Liu¹⁶, Ze-guang Li¹⁷, Zhong-wen Zhao¹⁸, Cheng-wu Wang¹⁹, Wei-chao Liu²⁰, Hai-dong Wang²¹, Yu-qian Lou²², Qing-liang Meng²³, Chong-jie Ruan²⁴, Yan-ming Xie²⁵ and Quan Jiang²⁶, ¹Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ³The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Heifei, China, ⁴Rheumatology, The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, China, ⁵Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, ⁶Rheumatology, Peking University People's Hospital, Beijing, China, ⁷Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ⁸Rheumatology, Southwest Hospital, Third Military Medical University, chongqing, China, ⁹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁰Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ¹¹Rheumatology, Bethune international peace hospital, Shi jiazhuang, China, ¹²Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China, ¹³Rheumatology, The Ninth People's Hospital of Chongqing City, Chongqing, China, ¹⁴Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, ¹⁵Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ¹⁶Rheumatology, The Affiliated Hospital of Shangdong University of Traditional Chinese Medicine, Qingdao, China, ¹⁷Rheumatology, The First Affiliated Hospital of Hei Longjiang University of Traditional Chinese Medicine, Ha Erbin, China, ¹⁸Rheumatology, The Second People's Hospital of Fujian Province, Fujian, China, ¹⁹Rheumatology, The First Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China, ²⁰Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China, ²¹Rheumatology, Gansu Provincial Hospital of Traditional Chinese Medicine, Shanxi, China, ²²Henan Rheumatism Hospital, Zhengzhou, China, ²³Rheumatology, Henan Provincial Hospital of Traditional Chinese Medicine, Zhengzhou, China, ²⁴Rheumatology and Pain Management Department, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China, ²⁵Clinical Evaluation Center, China Academy of Chinese Medical Sciences, Beijing, China, ²⁶Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: The use of patient reported outcomes(PROs) has become increasingly popular in the chronic disease management, disease monitoring and the assessment of drug efficacy. However,…
Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…
Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Catherine E. Najem¹, Wenjun Ju², Viji Nair², David Cuthbertson³, Rennie L. Rhee¹, Laura Mariani⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁵, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹, Steven R. Ytterberg¹⁴, Jeffrey Krischer¹⁵, Matthias Kretzler⁴ and Peter A. Merkel¹⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Michigan, Ann Arbor, MI, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Boston University School of Medicine, Boston, MA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵University of South Florida, Tampa, FL, ¹⁶Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…
Abstract Number: 2372 • 2017 ACR/ARHP Annual Meeting
Obesity and the Impact on Treat to Target Goals and Functional Ability in RA. Results from Two Multi-Centre UK Inception Cohorts
Elena Nikiphorou¹, Sam Norton², Patrick Kiely³ and Adam Young⁴, ¹Academic Rheumatology Department, King's College London, London, United Kingdom, ²Academic Rheumatology, King´s College London, London, United Kingdom, ³St George's Hospital, London, United Kingdom, ⁴University of Hertfordshire, Hertford, United Kingdom
Background/Purpose: The links between inflammation, obesity and joint dysfunction are well established. How these translate into clinical disease activity and functional disability in rheumatoid arthritis…
Abstract Number: 2625 • 2017 ACR/ARHP Annual Meeting
Predicting Flares in Patients with Stable Systemic Lupus Erythematosus
Jiacai Cho¹, Manjari Lahiri¹, Lay Kheng Teoh¹, Preeti Dhanasekaran^2,3, Pak Moon Peter Cheung¹ and Aisha Lateef¹, ¹Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ²National University of Singapore, singapore, Singapore, ³National University Hospital of Singapore, Singapore, Singapore
Background/Purpose: The course of systemic lupus erythematosus (SLE) varies with periods of quiescence punctuated by flares. Predicting exacerbations allows clinicians to select patients who need…
Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting
Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Edward C. Keystone¹, H Ahmad², Yusuf Yazici³, X Liu² and MJ Bergman⁴, ¹University of Toronto, Toronto, ON, Canada, ²Bristol-Myers Squibb, Princeton, NJ, ³New York University School of Medicine, New York, NY, ⁴Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].